Cardiotoxicity from the cardiologist's perspective

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 425-432

  Codón, Juan Caro ^a   Rodríguez, Sandra O Rosillo ^a   Fernández, Teresa López ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Anthracyclines; Biomarkers; Cardiotoxicity; Chemotherapy; Diagnosis; Echocardiography; Global longitudinal strain; Radiotherapy; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ARTICLE; CANCER PATIENT; CARDIOLOGIST; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMAGING; MYOCARDIAL DISEASE; PRIORITY JOURNAL; RADIATION INJURY; SCREENING TEST; TREATMENT OUTCOME; CARDIAC IMAGING; HEART DISEASES; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CARDIAC IMAGING TECHNIQUES; CARDIOTOXICITY; HEART DISEASES; HUMANS; NEOPLASMS;

EID: 84939456386     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.47     Document Type: Article

References (33)

1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J. Natl Cancer Inst. 102(1), 14-25 (2010).
2. Herrmann J, Lerman A, Sandhu NP et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin. Proc. 89(9), 1287-1306 (2014).
3. Sawyer D. Anthracyclines and heart failure. N. Engl. J. Med. 368(12), 1154-1156 (2013).
4. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson cancer center experience. J. Clin. Oncol. 24(25), 4107-4115 (2006).
5. Polk A1, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol. Toxicol. 15, 47 (2014).
6. Choueiri TK, Mayer EL, Je Y et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J. Clin. Oncol. 29(6), 632-638 (2011).
7. Greineder CF, Kohnstamm S, Ky B. Heart failure associated with sunitinib: lessons learned from animal models. Curr. Hypertens. Rep. 13(6), 436-441 (2011).
8. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 27(9), 911-939 (2014).
9. Kou S, Caballero L, Dulgheru R et al. Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. Eur. Heart J. Cardiovasc. Imaging 15(6), 680-690 (2014).
10. Lang R, Badano L, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 28(1), 1-39 (2015).
11. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. 23(13), 2900-2902 (2005).
12. Lal H, Kolaja K, Force T. Cancer genetics and the cardiotoxicity of the therapeutics. J. Am. Coll. Cardiol. 61(3), 267-274 (2013).
13. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 55(3), 213-220 (2010).
14. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39-51 (2007).
15. Oreto L, Todaro MC, Umland MM et al. Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know? J. Am. Soc. Echocardiogr. 25(11), 1141-1152 (2012).
16. Daher IN, Kim C, Saleh RR, Plana JC, Yusuf SW, Banchs J. Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients. Echocardiography 28(10), 1061-1067 (2010).
17. Senior R, Becher H, Monaghan M et al. Contrast echocardiography: evidence based recommendations by European Association of Echocardiography. Eur. J. Echocardiogr. 10(2), 194-212 (2009).
18. Lang R, Mor-Avi V, Dent JM, Kramer CM. Three-dimensional echocardiography: is it ready for everyday clinical use? JACC Cardiovasc. Imaging 2(1), 114-117 (2009).
19. Badano L, Boccalini F, Muraru D et al. Current clinical applications of transthoracic three-dimensional echocardiography. J. Cardiovasc. Ultrasound 20(1), 1-22 (2012).
20. Lang R, Badano L, Tsang W et al. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J. Am. Soc. Echocardiogr. 25(1), 3-46 (2012).
21. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popoviv ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes application to patients undergoing cancer chemotherapy. J. Am. Coll. Cardiol. 61(1), 77-84 (2013).
22. Mor-Avi V, Lang R, Badano L et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J. Am. Soc. Echocardiogr. 24(3), 277-313 (2011).
23. Yingchoncharoen T, Agarwal S, Popovi Z B, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J. Am. Soc. Echocardiogr. 26(2), 185-191 (2013).
24. Kang Y, Xu X, Cheng L et al. Twodimensional speckle tracking echocardiography combined with highsensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Eur. J. Heart Fail. 16(3), 300-308 (2014).
25. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy-a systematic review. J. Am. Coll. Cardiol. 63(25PtA), 2751-2768 (2014).
26. Colombo A, Sandri M, Salvatici M, Cipolla C, Cardinale D. Cardiac complications of chemotherapy: role of biomarkers. Curr. Treat. Options Cardiovasc. Med. 16(6), 313 (2014).
27. Lancellotti P, Nkomo VT, Badano L et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 26(9), 1013-1032 (2013).
28. Darby SC, Ewertz M, McGale P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368(11), 987-998 (2013).
29. Truong J, Yan AT, Cramarossa G, Chan KK. Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can. J. Cardiol. 30(8), 869-878 (2014).
30. Borras J M, Albreht T, Audisio R et al. European policy statement on multidisciplinary cancer care. European Partnership Action Against Cancer: Consensus group. Eur. J. Cancer. 50(3), 475-480. (2014).
31. Eschenhagen T, Force T, Ewer MS et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 13(1), 1-10 (2011).
32. Yancy C W, Jessup M, Bozkurt B et al. 2013 ACCF/AHA heart failure guidelines: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62(16), 1495-1539 (2013).
33. Bosch X, Rovira M, Sitges M et al. Enalapril and carvedilol for preventing chemotherapyinduced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 61(23), 2355-2362 (2013).